CDIO

Cardio Diagnostics Holdings Inc. is a precision cardiovascular medicine company leveraging artificial intelligence and genetic testing to develop clinical solutions for heart disease prevention. Headquartered in Chicago, Illinois, the company's proprietary Integrated Genetic-Epigenetic Engine analyzes multiple genetic and epigenetic markers to assess cardiovascular risk. Cardio Diagnostics' flagship product, PrecisionCHD, is a clinical test designed to assess three-year coronary heart disease risk in individuals. The company's approach combines genomics, bioinformatics, and machine learning to provide personalized cardiovascular risk assessments that can enable earlier intervention and more targeted treatment strategies. Cardio Diagnostics aims to improve patient outcomes by identifying at-risk individuals before symptoms appear. The company's technology platform has potential applications beyond coronary heart disease, including heart failure and other cardiovascular conditions. Cardio Diagnostics serves healthcare providers, patients, and potentially employers and health plans seeking to manage cardiovascular disease risk.